Introducing Auraseq - Fusions | Reshaping Patient Care





The AuraSeq-Fusions panel intended use is to detect a wide range of genomic alterations that are predictive biomarkers, as well as targets of tyrosine kinase inhibitors (TKI), in Non Small Cell Lung Cancer (NSCLC) and other advanced carcinomas from patients who have failed to respond to conventional chemotherapy or are about to start a personalized TKI regime.

This assay performs with 100% (95%CI 92.6%-100%) sensitivity and 93.8% (95%CI 69.8%-99.8%) speci city.


SNV's AND SMALL LABELS

CNV's

FUSIONS

AKT1

MAP2K1

ALK

ABL1

ALK

MAP2K2

AR

ALK

AR

MET

BRAF

AKT3

BRAF

MTOR

CCND1

AXL

CDK4

NRAS

CDK4

BRAF

CTNNB1

PDGFRA

CDK6

EGFR

DDR2

PIK3CA

EGFR

ERBB2

EGFR

RAF1

ERBB2

ERG

ERBB2

RET

FGFR1

ETV1

ERBB3

ROS1

FGFR2

ETV4

ERBB4

SMO

FGFR3

ETV5

ESR1

FGFR4

FGFR1

FGFR2

KIT

FGFR2

FGFR3

KRAS

FGFR3

GNA11

MET

MET

GNAQ

MYC

NTRK1

HRAS

MUCN

NTRK2

IDH1

PDGFRA

NTRK3

IDH2

PIK3CA

PDGFRA

JAK1

PPARG

JAK2

RAF1

JAK3

RET

KIT

ROS1

KRAS


For further information, please contact:


Jorge Almenara, Ph.D.
Strategic Accounts Manager
Aurora Diagnostics
M 804.551.1598
[email protected]

Brad Bernhardt
Director of Product Development
Aurora Diagnostics
M 904.813.3088
[email protected]